Vontobel Holding Ltd. Has $165,000 Holdings in Candel Therapeutics, Inc. (NASDAQ:CADL)

Vontobel Holding Ltd. lessened its position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 13.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,000 shares of the company’s stock after selling 3,000 shares during the quarter. Vontobel Holding Ltd.’s holdings in Candel Therapeutics were worth $165,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. HB Wealth Management LLC boosted its holdings in shares of Candel Therapeutics by 54.1% during the 4th quarter. HB Wealth Management LLC now owns 87,300 shares of the company’s stock worth $696,000 after buying an additional 30,642 shares in the last quarter. Barclays PLC boosted its holdings in shares of Candel Therapeutics by 327.1% during the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after buying an additional 21,971 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Candel Therapeutics by 12.8% during the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock worth $3,112,000 after buying an additional 51,111 shares in the last quarter. State Street Corp boosted its holdings in shares of Candel Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after buying an additional 19,207 shares in the last quarter. Finally, Atom Investors LP bought a new position in shares of Candel Therapeutics during the 3rd quarter worth approximately $103,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 20,392 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $4.56, for a total transaction of $92,987.52. Following the transaction, the chief technology officer now directly owns 125,657 shares in the company, valued at approximately $572,995.92. This trade represents a 13.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul B. Manning acquired 1,250,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were bought at an average price of $6.00 per share, for a total transaction of $7,500,000.00. Following the completion of the purchase, the director now owns 1,303,752 shares in the company, valued at approximately $7,822,512. This represents a 2,325.49 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 75,856 shares of company stock worth $470,044. Corporate insiders own 41.60% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on CADL shares. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a report on Wednesday, December 18th. Citigroup started coverage on Candel Therapeutics in a report on Thursday. They issued a “buy” rating and a $25.00 target price on the stock. Bank of America started coverage on Candel Therapeutics in a report on Friday, February 7th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Canaccord Genuity Group started coverage on Candel Therapeutics in a report on Wednesday. They issued a “buy” rating and a $20.00 target price on the stock.

Candel Therapeutics Trading Down 4.8 %

Shares of NASDAQ:CADL opened at $11.63 on Friday. The stock’s fifty day simple moving average is $8.20 and its two-hundred day simple moving average is $6.63. Candel Therapeutics, Inc. has a 1-year low of $1.34 and a 1-year high of $14.60. The stock has a market cap of $377.74 million, a PE ratio of -6.72 and a beta of -1.25.

Candel Therapeutics Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.